(Reuters) - The U.S. Securities and Exchange Commission on Friday sued Mylan NV (O:MYL), accusing it of failing to timely disclose a possible loss related to a Department of Justice probe into whether the company overcharged Medicaid by hundreds of millions of dollars for sales of the EpiPen Auto-Injector.
In a complaint filed with the federal court in Washington, D.C., the SEC accused Mylan of misclassifying EpiPen, which is used to treat severe allergic reactions, as a "generic" or "non-innovator" drug.
